NASDAQ:INVA

Innoviva - INVA Stock Forecast, Price & News

$12.40

+0.02 (+0.16%)

(As of 10/7/2022 12:00 AM ET)

Add

Compare

Today's Range: $12.22
▼
$12.48
50-Day Range: $11.61
▼
$14.79
52-Week Range: $11.56
▼
$20.71

Volume: 600,193 shs
Average Volume: 961,632 shs
Market Capitalization: $864.35 million

P/E Ratio: 9.61
Dividend Yield: N/A
Price Target: $13.00

Innoviva MarketRank™ Forecast

Analyst Rating: Hold
1.50 Rating Score
Upside/Downside: 4.8% Upside
$13.00 Price Target
Short Interest: Bearish
15.90% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.11
Upright™ Environmental Score
News Sentiment: 0.70
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: -74.61%
From $3.19 to $0.81 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.14 out of 5 stars

Medical Sector

1050th out of 1,072 stocks

Pharmaceutical Preparations Industry

519th out of 531 stocks

0.8

Analyst's Opinion

Consensus Rating
Innoviva has received a consensus rating of Hold. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $13.00, Innoviva has a forecasted upside of 4.8% from its current price of $12.40.
Amount of Analyst Coverage
Innoviva has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
15.90% of the float of Innoviva has been sold short.
Short Interest Ratio / Days to Cover
Innoviva has a short interest ratio ("days to cover") of 14.1, which indicates bearish sentiment.
Change versus previous month
Short interest in Innoviva has recently decreased by 5.01%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Innoviva does not currently pay a dividend.
Dividend Growth
Innoviva does not have a long track record of dividend growth.

1.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Innoviva has received a -23.69% net impact score from Upright. Innoviva uses resources or causes negative impacts mostly in categories "Scarce human capital", "Equality & human rights", and "GHG emissions". The negative contribution in the "Equality & human rights" impact category is driven by its "Private equity funds investing in the pharmaceuticals industry" product. See details.
Environmental Sustainability
The Environmental Impact score for Innoviva is -0.11.

3.2

News and Social Media Coverage

News Sentiment
Innoviva has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Innoviva this week, compared to 2 articles on an average week.
Search Interest
4 people have searched for INVA on MarketBeat in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Innoviva insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.89% of the stock of Innoviva is held by insiders.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Innoviva are expected to decrease by -74.61% in the coming year, from $3.19 to $0.81 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Innoviva is 9.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 118.47.
Price to Earnings Ratio vs. Sector
The P/E ratio of Innoviva is 9.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 92.93.
Price to Book Value per Share Ratio
Innoviva has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Innoviva (NASDAQ:INVA) Stock

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

INVA Stock News Headlines

October 5, 2022 | americanbankingnews.com

Innoviva, Inc. (NASDAQ:INVA) Sees Large Decline in Short Interest

September 29, 2022 | finance.yahoo.com

Gate Neurosciences Publishes Data Highlighting Novel Mechanism of Lead Rapid-Acting Oral Antidepressant and Provides Business Update - Yahoo Finance

September 27, 2022 | reuters.com

INVA.OQ - Innoviva Inc | Stock Price & Latest News | Reuters

September 19, 2022 | seekingalpha.com

Innoviva Stock? Not Yet. Short Puts? Definitely. (NASDAQ:INVA) - Seeking Alpha

September 8, 2022 | businesswire.com

Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference - Business Wire

August 29, 2022 | globenewswire.com

Chronic Obstructive Pulmonary Disease Drug Market exhibiting a CAGR of 6.8 % and is expected to reach USD 1.6 Billion by 2029 - GlobeNewswire

August 23, 2022 | benzinga.com

Innoviva Completes Acquisition of La Jolla...

August 22, 2022 | businesswire.com

Innoviva Completes Acquisition of La Jolla Pharmaceutical - Business Wire

August 1, 2022 | benzinga.com

Innoviva's Return On Capital Employed Overview - Benzinga

August 1, 2022 | nasdaq.com

Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals? - Nasdaq

July 28, 2022 | businesswire.com

Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress - Business Wire

July 27, 2022 | benzinga.com

Innoviva: Q2 Earnings Insights - Benzinga - Benzinga

July 27, 2022 | seekingalpha.com

Innoviva GAAP EPS of $0.05, revenue of $108.22M (NASDAQ:INVA) - Seeking Alpha

July 27, 2022 | apnews.com

Innoviva: Q2 Earnings Snapshot - The Associated Press - en Español

July 27, 2022 | finance.yahoo.com

Innoviva (INVA) Misses Q2 Earnings Estimates

July 25, 2022 | streetinsider.com

Form SC TO-T LA JOLLA PHARMACEUTICAL Filed by: Innoviva, Inc. - StreetInsider.com

July 21, 2022 | finance.yahoo.com

Could The Market Be Wrong About Innoviva, Inc. (NASDAQ:INVA) Given Its Attractive Financial Prospects?

July 20, 2022 | nasdaq.com

Earnings Preview: Innoviva (INVA) Q2 Earnings Expected to Decline - Nasdaq

July 20, 2022 | seekingalpha.com

Goldman Sachs starts Innoviva with neutral rating, says royalty portfolio fairly valued - Seeking Alpha

July 14, 2022 | benzinga.com

Over $42 Million Bet On This Biotechnology Stock? 4 Penny Stocks Insiders are Buying - Benzinga

July 13, 2022 | seekingalpha.com

Royalty Pharma to buy royalty interest in Trelegy drug from Theravance, Innoviva for $1.3B - Seeking Alpha

July 13, 2022 | businesswire.com

Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment - Business Wire

July 13, 2022 | finance.yahoo.com

Royalty Pharma Agrees to Acquire Royalty Interest in TRELEGY ELLIPTA From Theravance and Innoviva for $1.31 Billion and Potential Milestones of $300 Million

July 13, 2022 | finance.yahoo.com

July 11, 2022 | nasdaq.com

Health Care Sector Update for 07/11/2022: LJPC,INVA,ATNX,ITRM - Nasdaq

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

INVA Company Calendar

Last Earnings: 7/27/2022
Today: 10/07/2022
Next Earnings (Estimated): 10/26/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:INVA
Previous Symbol: NASDAQ:THRX
CUSIP: 88338T10
CIK: 1080014
Web: www.inva.com
Phone: (650) 238-9600
Fax: 650-827-8690
Employees: 5
Year Founded: 1996

Price Target and Rating

Average Stock Price Forecast: $13.00
High Stock Price Forecast: $13.00
Low Stock Price Forecast: $13.00
Forecasted Upside/Downside: +4.8%
Consensus Rating: Hold
Rating Score (0-4): 1.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.29
Trailing P/E Ratio: 9.61
Forward P/E Ratio: 3.89
P/E Growth: N/A
Net Income: $265.85 million
Net Margins: 24.64%
Pretax Margin: 60.64%
Return on Equity: 28.86%
Return on Assets: 15.19%

Debt

Debt-to-Equity Ratio: 0.78
Current Ratio: 3.18
Quick Ratio: 3.18

Sales & Book Value

Annual Sales: $391.87 million
Price / Sales: 2.21
Cash Flow: $4.71 per share
Price / Cash Flow: 2.63
Book Value: $7.56 per share
Price / Book: 1.64

Miscellaneous

Outstanding Shares: 69,706,000
Free Float: 69,086,000
Market Cap: $864.35 million
Optionable: Optionable
Beta: 0.53

Social Links

Key Executives

Mr. Pavel Raifeld C.F.A. (Age 38)
Chief Exec. Officer
Comp: $690.81k

Ms. Marianne Zhen CPA (Age 53)
Chief Accounting Officer & Sec.
Comp: $462.18k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INVA Stock - Frequently Asked Questions

Should I buy or sell Innoviva stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" INVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INVA, but not buy additional shares or sell existing shares.
View INVA analyst ratings or view top-rated stocks.
What is Innoviva's stock price forecast for 2022?: 2 equities research analysts have issued 12 month price targets for Innoviva's shares. Their INVA share price forecasts range from $13.00 to $13.00. On average, they anticipate the company's stock price to reach $13.00 in the next year. This suggests a possible upside of 5.3% from the stock's current price.
View analysts price targets for INVA or view top-rated stocks among Wall Street analysts.
How have INVA shares performed in 2022?: Innoviva's stock was trading at $17.25 at the beginning of the year. Since then, INVA shares have decreased by 28.5% and is now trading at $12.34.
View the best growth stocks for 2022 here.
When is Innoviva's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our INVA earnings forecast.
How were Innoviva's earnings last quarter?: Innoviva, Inc. (NASDAQ:INVA) announced its quarterly earnings data on Wednesday, July, 27th. The biotechnology company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.55 by $0.50. The biotechnology company had revenue of $108.22 million for the quarter, compared to analysts' expectations of $103.42 million. Innoviva had a trailing twelve-month return on equity of 28.86% and a net margin of 24.64%.

What other stocks do shareholders of Innoviva own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).
What is Innoviva's stock symbol?: Innoviva trades on the NASDAQ under the ticker symbol "INVA."
Who are Innoviva's major shareholders?: Innoviva's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Exchange Traded Concepts LLC (0.26%). Insiders that own company stock include George Bickerstaff, Innoviva, Inc, Marianne Zhen and Plc Glaxosmithkline.
View institutional ownership trends.
How do I buy shares of Innoviva?: Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Innoviva's stock price today?: One share of INVA stock can currently be purchased for approximately $12.34.
How much money does Innoviva make?: Innoviva (NASDAQ:INVA) has a market capitalization of $860.22 million and generates $391.87 million in revenue each year. The biotechnology company earns $265.85 million in net income (profit) each year or $1.29 on an earnings per share basis.
How can I contact Innoviva?: Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The official website for the company is www.inva.com. The biotechnology company can be reached via phone at (650) 238-9600, via email at investor.relations@inva.com, or via fax at 650-827-8690.

This page (NASDAQ:INVA) was last updated on 10/7/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Innoviva - INVA Stock Forecast, Price & News

Innoviva MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability